A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Status:
Not yet recruiting

Trial end date:
2027-02-07

Target enrollment:

Participant gender:

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Phase 3

Amgen

KHK4083